Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jan;59(1):106–109. doi: 10.1038/bjc.1989.21

Myoglobin: an evaluation of its role as a marker of rhabdomyosarcomas.

M Leader 1, J Patel 1, M Collins 1, K Henry 1
PMCID: PMC2246963  PMID: 2757915

Abstract

Tumour markers now have an established role in tumour diagnosis and patient management. However, antibodies used to detect these tumour markers have in some instances proved unreliable, with a low rate of sensitivity and specificity. In this study we wished to evaluate the role of a commercial antibody to myoglobin as a marker of rhabdomyosarcomas. The purpose of this investigation was to assess the sensitivity and specificity of myoglobin antiserum as a marker of rhabdomyosarcomas. This was performed by reacting a large number of tumours (sarcomas, carcinomas and melanomas) with a polyclonal anti human myoglobin antiserum. Staining was demonstrated in 60% of rhabdomyosarcomas. Only two tumours from a total of 226 non-skeletal muscle tumours showed a positive reaction (0.88%). One was a leiomyosarcoma and the other had been classified as an undifferentiated sarcoma but a rhabdomyosarcoma was included in its differential diagnosis. It is of interest that both had been earlier irradiated. This antiserum was therefore a specific but not a very sensitive tumor marker. Its rate of staining of rhabdomyosarcomas is compared with the results in the literature. A great disparity is found and the reasons for this are discussed.

Full text

PDF
106

Images in this article

108Figure 1
on p.108
108Figure 2
on p.108
108Figure 3
on p.108

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brooks J. J. Immunohistochemistry of soft tissue tumors. Myoglobin as a tumor marker for rhabdomyosarcoma. Cancer. 1982 Nov 1;50(9):1757–1763. doi: 10.1002/1097-0142(19821101)50:9<1757::aid-cncr2820500919>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  2. Corson J. M., Pinkus G. S. Intracellular myoglobin--a specific marker for skeletal muscle differentiation in soft tissue sarcomas. An immunoperoxidase study. Am J Pathol. 1981 Jun;103(3):384–389. [PMC free article] [PubMed] [Google Scholar]
  3. Dias P., Kumar P., Marsden H. B., Morris-Jones P. H., Birch J., Swindell R., Kumar S. Evaluation of desmin as a diagnostic and prognostic marker of childhood rhabdomyosarcomas and embryonal sarcomas. Br J Cancer. 1987 Sep;56(3):361–365. doi: 10.1038/bjc.1987.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eusebi V., Bondi A., Rosai J. Immunohistochemical localization of myoglobin in nonmuscular cells. Am J Surg Pathol. 1984 Jan;8(1):51–55. doi: 10.1097/00000478-198401000-00005. [DOI] [PubMed] [Google Scholar]
  5. Jong A. S., van Vark M., Albus-Lutter C. E., van Raamsdonk W., Voûte P. A. Myosin and myoglobin as tumor markers in the diagnosis of rhabdomyosarcoma. A comparative study. Am J Surg Pathol. 1984 Jul;8(7):521–528. doi: 10.1097/00000478-198407000-00004. [DOI] [PubMed] [Google Scholar]
  6. Kagawa N., Sano T., Inaba H., Mori K., Hizawa K. Immunohistochemistry of myoglobin in rhabdomyosarcomas. Acta Pathol Jpn. 1983 May;33(3):515–522. doi: 10.1111/j.1440-1827.1983.tb00358.x. [DOI] [PubMed] [Google Scholar]
  7. Kahn H. J., Yeger H., Kassim O., Jorgensen A. O., MacLennan D. H., Baumal R., Smith C. R., Phillips M. J. Immunohistochemical and electron microscopic assessment of childhood rhabdomyosarcoma. Increased frequency of diagnosis over routine histologic methods. Cancer. 1983 May 15;51(10):1897–1903. doi: 10.1002/1097-0142(19830515)51:10<1897::aid-cncr2820511023>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  8. Kindblom L. G., Seidal T., Karlsson K. Immuno-histochemical localization of myoglobin in human muscle tissue and embryonal and alveolar rhabdomyosarcoma. Acta Pathol Microbiol Immunol Scand A. 1982 May;90(3):167–174. doi: 10.1111/j.1699-0463.1982.tb00078_90a.x. [DOI] [PubMed] [Google Scholar]
  9. Leader M., Collins M., Patel J., Henry K. Antineuron specific enolase staining reactions in sarcomas and carcinomas: its lack of neuroendocrine specificity. J Clin Pathol. 1986 Nov;39(11):1186–1192. doi: 10.1136/jcp.39.11.1186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Leader M., Collins M., Patel J., Henry K. Desmin: its value as a marker of muscle derived tumours using a commercial antibody. Virchows Arch A Pathol Anat Histopathol. 1987;411(4):345–349. doi: 10.1007/BF00713379. [DOI] [PubMed] [Google Scholar]
  11. Leader M., Collins M., Patel J., Henry K. Staining for factor VIII related antigen and Ulex europaeus agglutinin I (UEA-I) in 230 tumours. An assessment of their specificity for angiosarcoma and Kaposi's sarcoma. Histopathology. 1986 Nov;10(11):1153–1162. doi: 10.1111/j.1365-2559.1986.tb02555.x. [DOI] [PubMed] [Google Scholar]
  12. Leader M., Collins M., Patel J., Henry K. Vimentin: an evaluation of its role as a tumour marker. Histopathology. 1987 Jan;11(1):63–72. doi: 10.1111/j.1365-2559.1987.tb02609.x. [DOI] [PubMed] [Google Scholar]
  13. Leader M., Patel J., Collins M., Henry K. Anti-alpha 1-antichymotrypsin staining of 194 sarcomas, 38 carcinomas, and 17 malignant melanomas. Its lack of specificity as a tumour marker. Am J Surg Pathol. 1987 Feb;11(2):133–139. doi: 10.1097/00000478-198702000-00007. [DOI] [PubMed] [Google Scholar]
  14. Leader M., Patel J., Collins M., Kristin H. Synovial sarcomas. True carcinosarcomas? Cancer. 1987 Jun 15;59(12):2096–2098. doi: 10.1002/1097-0142(19870615)59:12<2096::aid-cncr2820591222>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  15. Leader M., Patel J., Makin C., Henry K. An analysis of the sensitivity and specificity of the cytokeratin marker CAM 5.2 for epithelial tumours. Results of a study of 203 sarcomas, 50 carcinomas and 28 malignant melanomas. Histopathology. 1986 Dec;10(12):1315–1324. doi: 10.1111/j.1365-2559.1986.tb02574.x. [DOI] [PubMed] [Google Scholar]
  16. Russell W. O., Cohen J., Enzinger F., Hajdu S. I., Heise H., Martin R. G., Meissner W., Miller W. T., Schmitz R. L., Suit H. D. A clinical and pathological staging system for soft tissue sarcomas. Cancer. 1977 Oct;40(4):1562–1570. doi: 10.1002/1097-0142(197710)40:4<1562::aid-cncr2820400428>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  17. Tsokos M., Howard R., Costa J. Immunohistochemical study of alveolar and embryonal rhabdomyosarcoma. Lab Invest. 1983 Feb;48(2):148–155. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES